Micro-current control method, cornea iontophoresis system, electronic equipment and medium

Abstract

The invention provides a micro-current control method, a corneal iontophoresis system, electronic equipment and a medium, the micro-current control method is applied to a riboflavin iontophoresis device in corneal crosslinking, and the riboflavin iontophoresis device comprises a micro-current controller; the micro-current controller is electrically connected with the direct-current power supply and is used for converting constant current provided by the direct-current power supply into micro-current; the micro-current control method comprises the following steps: monitoring the current change of the output end of a micro-current controller in real time; monitoring the skin impedance change of the patient when the micro-current flows through the treatment area in real time; based on the current change and / or the skin impedance change, performing standard evaluation on the magnitude of the micro-current acting on the treatment area; and dynamically adjusting the micro-current which does not meet the standard so as to realize standard output of the micro-current. According to the application, by dynamically adjusting the magnitude of the micro-current, stable control of the current in the process of introducing riboflavin ions into the cornea is realized, and the safety and effectiveness of epithelial administration of riboflavin are improved.

Description

Technical Field

[0001] The present application relates to the field of medical device technology, and in particular to a microcurrent control method, a corneal ion introduction system, an electronic device and a medium. Background Art

[0002] Corneal Cross-Linking (CXL) is an effective treatment for ectatic keratopathy. It uses the synergistic effect of ultraviolet irradiation and riboflavin to promote the formation of a tighter cross-linked structure between collagen fibers in the corneal stroma, thereby enhancing the overall strength and stability of the cornea.

[0003] Traditional corneal cross-linking mainly includes epithelial removal surgery and transepithelial surgery. Epithelial removal surgery requires scraping the patient's corneal epithelium, so the postoperative recovery period is longer, and the patient's pain and discomfort are more obvious. In addition, the loss of the corneal epithelium exposes the corneal surface, thereby increasing the risk of postoperative infection. In contrast, transepithelial surgery, as a non-invasive corneal cross-linking method, significantly reduces the patient's postoperative pain and discomfort, and reduces the risk of infection caused by the loss of the corneal epithelium, but the riboflavin penetration time is longer.

[0004] The above two traditional corneal cross-linking procedures both use a method of administering riboflavin by dripping it and then waiting for it to penetrate. This process is relatively slow and may lead to a prolonged treatment time. In addition, due to individual differences, the corneal structure and physiological state of different patients are different, and the effect of natural penetration will also vary from person to person. Some individuals may have low natural penetration efficiency and riboflavin may not be able to completely penetrate the corneal stroma for a long time.

[0005] According to existing research results, the penetration efficiency of riboflavin ion introduction in corneal cross-linking surgery can be increased by 2 times compared with traditional transepithelial surgery. The principle of ion introduction of riboflavin is to use the electric field to drive the charged riboflavin ions through the corneal epithelium and enter the corneal stroma under the drive of electric current. However, when the driving current of riboflavin ions is abnormal, the penetration effect of riboflavin ions will be uneven, which will cause the final treatment effect to fail to meet expectations. Summary of the invention

[0006] The purpose of the present application is to provide a microcurrent control method, a corneal ion introduction system, an electronic device and a medium, which are used to solve the current abnormality problem existing in the prior art during the riboflavin ion introduction process.

[0007] In a first aspect, the present application provides a microcurrent control method, which is applied to a riboflavin ion introduction device in corneal cross-linking surgery, characterized in that the riboflavin ion introduction device includes a microcurrent controller; the microcurrent controller is electrically connected to a DC power supply, and is used to convert the constant current provided by the DC power supply into a microcurrent; the microcurrent control method includes: real-time monitoring of current changes at the output end of the microcurrent controller; real-time monitoring of changes in the patient's skin impedance when the microcurrent flows through the treatment area; based on the current changes and / or the skin impedance changes, a standard evaluation of the size of the microcurrent acting on the treatment area is performed; and the microcurrent that does not meet the standards is dynamically adjusted to achieve standard output of the microcurrent.

[0008] In an implementation of the first aspect, real-time monitoring of current changes at the output end of the microcurrent controller includes: collecting the original current signal output by the microcurrent controller as a first current signal; digitally processing the first current signal to obtain a corresponding first current value; storing the first current value in a first array of preset capacity in chronological order of collection time; calculating the standard deviation value of all samples in the first array in real time; and dynamically updating the first array based on the first-in-first-out principle.

[0009] In an implementation of the first aspect, based on the current change, a standard evaluation of the size of the microcurrent acting on the treatment area includes: determining whether the current value stored in the first array is always zero; if so, issuing an electrode disconnection warning; otherwise, comparing the standard variance value with a preset tolerance range; if the standard variance value is greater than the preset tolerance range, determining that the size of the microcurrent acting on the treatment area does not meet the standard, and issuing a current fluctuation warning; otherwise, determining that the size of the microcurrent acting on the treatment area meets the standard.

[0010] In an implementation of the first aspect, real-time monitoring of changes in the patient's skin impedance when the microcurrent flows through the treatment area includes: collecting the current signal flowing through the treatment area as a second current signal; digitally processing the second current signal to obtain a corresponding second current value; storing the second current value in a second array of preset capacity in the order of collection time; calculating the average value of all samples in the second array to obtain a current average value; dynamically updating the second array based on the first-in-first-out principle; collecting the voltage drop signal at both ends of the output end of the microcurrent controller; digitally processing the voltage drop signal to obtain a corresponding voltage drop value; storing the voltage drop value in a third array of preset capacity in the order of collection time; calculating the average value of all samples in the third array to obtain a voltage drop average value; dynamically updating the third array based on the first-in-first-out principle; and calculating the skin impedance value based on the current average value and the voltage drop average value.

[0011] In an implementation of the first aspect, based on the change in skin impedance, a standard evaluation of the size of the microcurrent acting on the treatment area includes: comparing the skin impedance value with a preset normal range; if the skin impedance value is within the preset normal range, it is determined that the size of the microcurrent acting on the treatment area meets the standard; otherwise, it is determined that the size of the microcurrent acting on the treatment area does not meet the standard, and a poor contact warning is issued.

[0012] In an implementation of the first aspect, dynamically adjusting the microcurrent that does not meet the standards to achieve standard output of the microcurrent includes: if the skin impedance value is higher than the preset normal range, reducing the resistance value of the digital potentiometer to increase the value of the microcurrent; the resistance value of the digital potentiometer is inversely proportional to the value of the microcurrent; if the skin impedance value is lower than the preset normal range, increasing the resistance value of the digital potentiometer to reduce the value of the microcurrent.

[0013] In an implementation of the first aspect, dynamically adjusting the microcurrent that does not meet the standards to achieve stable output of the microcurrent includes: comparing the current average value with a preset target treatment current parameter, and determining whether the current average value is within the target current tolerance range; if the current average value>the target treatment current parameter, and the current average value is outside the target current tolerance range, increasing the resistance value of the digital potentiometer to reduce the value of the microcurrent; if the current average value<the target treatment current parameter, and the current average value is outside the target current tolerance range, reducing the resistance value of the digital potentiometer to increase the value of the microcurrent; if the current average value is within the target current tolerance range, maintaining the resistance value of the digital potentiometer unchanged.

[0014] In a second aspect, the present application provides a corneal ion introduction system, comprising: a DC power supply, the DC power supply is used to provide a constant current; a riboflavin ion introduction device, the riboflavin ion introduction device includes a microcurrent controller; the microcurrent controller is electrically connected to the DC power supply, and is used to execute any of the microcurrent control methods described above.

[0015] In an implementation of the second aspect, the riboflavin ion introduction device also includes a corneal drug delivery device; the corneal drug delivery device includes a reservoir for storing riboflavin solution, a negative electrode network and an electrical connector; the bottom of the reservoir is provided with a fitting surface for fitting the cornea, and the upper end of the reservoir is formed with a drug delivery port; the negative electrode network is embedded in the reservoir and in contact with the riboflavin solution in the reservoir; the electrical connector is provided on the outer wall of the reservoir and is connected to the negative electrode network.

[0016] In an implementation of the second aspect, the microcurrent controller includes an input end and two output ends, wherein the input end is connected to the DC power supply, one output end is electrically connected to the negative electrode network through the electrical connector, and the other output end is electrically connected to the patient's skin.

[0017] In a third aspect, the present application provides an electronic device, comprising: a memory for storing computer programs and firmware programs; and a processor for executing the computer programs stored in the memory so that the electronic device performs any of the microcurrent control methods described above.

[0018] In a fourth aspect, the present application provides a computer-readable storage medium having a computer program stored thereon, wherein the computer program and the firmware program, when executed by a processor, implement any of the above-described microcurrent control methods.

[0019] As described above, the microcurrent control method, corneal ion introduction system, electronic device and medium described in the present application achieve standard current output during riboflavin ion introduction into the cornea by dynamically adjusting the magnitude of the microcurrent, thereby improving the safety and effectiveness of riboflavin transepithelial administration. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Shown is a schematic structural diagram of a corneal ion introduction system according to an embodiment of the present application.

[0021] Figure 2 Shown is a schematic diagram of ion migration during the riboflavin ion introduction process into the cornea described in the present application in one embodiment.

[0022] Figure 3 Shown is a schematic structural diagram of a mobile terminal described in the present application in one embodiment.

[0023] Figure 4 Shown is a flow chart of a microcurrent control method described in the present application in one embodiment.

[0024] Figure 5 Shown is a flow chart of another embodiment of the microcurrent control method described in the present application.

[0025] Figure 6 Shown is a flow chart of another embodiment of the microcurrent control method described in the present application.

[0026] Figure 7 Shown is a flow chart of the microcurrent control method described in the present application in yet another embodiment.

[0027] Figure 8 Shown is a schematic structural diagram of an electronic device described in this application in an embodiment. DETAILED DESCRIPTION

[0028] The following describes the embodiments of the present application through specific examples, and those skilled in the art can easily understand other advantages and effects of the present application from the contents disclosed in this specification. The present application can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present application. It should be noted that the following embodiments and features in the embodiments can be combined with each other without conflict.

[0029] It should be noted that the illustrations provided in the following embodiments are only schematic illustrations of the basic concept of the present application, and thus the drawings only show components related to the present application rather than being drawn according to the number, shape and size of components in actual implementation. In actual implementation, the type, quantity and proportion of each component may be changed at will, and the component layout may also be more complicated.

[0030] In addition, in this application, descriptions such as "first", "second", etc. are only used for descriptive purposes and cannot be understood as indicating or implying their relative importance or implicitly indicating the number of technical features indicated. Therefore, the features defined as "first" and "second" may explicitly or implicitly include at least one of the features. In addition, the technical solutions between the various embodiments can be combined with each other, but they must be based on the ability of ordinary technicians in this field to implement them. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such combination of technical solutions does not exist and is not within the scope of protection required by this application.

[0031] In corneal cross-linking, the corneal iontophoresis system uses iontophoresis technology to treat ectatic corneal diseases such as keratoconus. The principle of the iontophoresis technology is based on the action of a DC electric field, which causes charged chemical drugs or drug ions to move under the influence of the electric field. This process does not require drugs to circulate through the blood, but allows them to pass through specific human tissues and accurately introduce charged drug ions into a given tissue or area, thereby assisting in achieving a therapeutic effect. During this process, the drug can maintain a high concentration in the tissue and last for a long time.

[0032] See also Figure 1 , which is a schematic diagram of the structure of the corneal ion introduction system described in the present application in one embodiment. Figure 1 As shown, the corneal ion introduction system provided in the embodiment of the present application includes a DC power supply and a riboflavin ion introduction device. The DC power supply is used to provide a constant current. The riboflavin ion introduction device includes a microcurrent controller; the microcurrent controller is electrically connected to the DC power supply and is used to convert the constant current provided by the DC power supply into a microcurrent.

[0033] The following embodiments of the present application provide a microcurrent control method, a corneal ion introduction system, an electronic device and a medium. The microcurrent control method is applied to a riboflavin ion introduction device in corneal cross-linking surgery.

[0034] Specifically, the riboflavin ion introduction device also includes a corneal drug delivery device. The corneal drug delivery device includes a reservoir for storing riboflavin solution, a negative electrode net and an electrical connector; the bottom of the reservoir is provided with a fitting surface for fitting the cornea, and the upper end of the reservoir is formed with a drug delivery port; the negative electrode net is embedded in the reservoir and contacts the riboflavin solution in the reservoir; the electrical connector is provided on the outer side wall of the reservoir and communicates with the negative electrode net.

[0035] The microcurrent controller includes an input end and two output ends, wherein the input end is connected to the DC power supply, one of the output ends is electrically connected to the negative electrode network through the electrical connector, and the other of the output ends is electrically connected to the patient's skin. The microcurrent controller is used to execute the microcurrent control method described in the present application.

[0036] The present application achieves standard current output during the introduction of riboflavin ions into the cornea by dynamically adjusting the size of the microcurrent, thereby improving the safety and effectiveness of transepithelial administration of riboflavin.

[0037] Before further describing the present application in detail, the nouns and terms that may be involved in the embodiments of the present application are explained to facilitate understanding of the technical solutions provided by the embodiments of the present application.

[0038] <1> The cornea is one of the biological membranes of the human eye. The surface of its corneal epithelial cells contains glycosaminoglycans (such as hyaluronic acid in the corneal stroma) and sulfated glycosaminoglycans. These negatively charged components can form electrostatic interactions with surrounding cations. Therefore, the surface of the corneal epithelium carries a negative charge.

[0039] <2> The sclera is another important biological membrane in the human eye, and together with the cornea, it forms the wall of the eyeball. The proteins and glycosaminoglycans in the sclera can show a certain negative charge, especially when interacting with drugs or electric fields, which can affect the drug's penetration per unit time and overall penetration effect. When the cornea is damaged or there are certain diseases that cause changes in corneal permeability, the sclera can serve as an important drug penetration pathway.

[0040] <3> Riboflavin (Rf), as a negatively charged ion, moves from the reservoir to the inside of the cornea under the action of the electric field. Ions on the surface of the cornea, such as Na+ (sodium ions), also move (move upward) in the electric field, while the drug riboflavin ions are pushed into the deep tissues of the cornea. Figure 2 A schematic diagram of ion migration in one embodiment of the riboflavin ion introduction process into the cornea described in the present application is shown.

[0041] <4> In corneal cross-linking applications, a greater riboflavin drug flux means a shorter treatment time and better penetration. The formula for calculating drug flux during corneal ion introduction is as follows:

[0042]

[0043] Among them J TOT It represents the total drug flux, that is, the amount of drug passing through the tissue (such as cornea or skin) per unit time (usually in mol / cm2·s). I represents the current intensity. The current directly affects the drug transmission rate. The higher the current, the greater the ion migration rate. However, due to the physical properties of the cornea, this corneal ion introduction system controls the current to 1mA or less, and uses microcurrent to perform treatment without causing damage to the cornea. A represents the area of ​​the drug application region, which is the effective surface area through which the drug passes (unit: cm 2 ). The larger the area, the smaller the distribution of drug flux per unit area (the current distribution is more dispersed). The traditional riboflavin administration method uses a drip method to drip riboflavin solution onto the cornea, but the drug density per unit area on the corneal surface will gradually decrease as riboflavin flows to non-target areas. However, in this corneal ion introduction system, the annular bottom diameter of the drug delivery device is fixed on the corneal surface, so the drug will be stored within the reservoir and will not flow out. The drug density per unit area on the cornea is accurately maintained, as well as the uniform introduction current, ultimately resulting in a more efficient penetration effect. F represents the Faraday constant, the conversion constant between charge and molar number, F = 96,485C / mol. u drug Indicates the electrical mobility of the drug, the migration ability of drug ions in an electric field, and the unit is usually cm2 / V·s. ∑∈ i u i Z i Represents the effect of competing ions, which is equal to the weighted sum of the mobility, concentration, and charge of all ions (including drug ions and competing ions). A→C Represents the natural diffusion flux. Even without the presence of current, the drug will diffuse naturally from the application area (A) to the target area (C) due to the concentration gradient. drug Indicates the concentration of the drug, the initial concentration in the drug solution, in mol / L. Without changing any factors of the drug, the drug flux without current = V A→C ·C drug .

[0044] The microcurrent control method provided in the embodiment of the present application can be run in a mobile terminal, a computer terminal, or similar devices. Taking running on the mobile terminal as an example, Figure 3 is a schematic diagram of the structure of the mobile terminal, such as Figure 3 Taking the mobile terminal as an example, the mobile terminal may include: a processor and a memory, wherein the processor may be a central processing unit, and the memory is used to store data. Figure 3The mobile terminal in the figure is only used as an example and does not limit the specific structure of the mobile terminal.

[0045] Optionally, the mobile terminal may further include: a user interaction module and an input / output module.

[0046] Optionally, the memory may be used to store computer programs, such as software programs and modules of application software, and the memory may include high-speed random access memory, and may also include non-volatile memory, such as one or more magnetic storage devices, flash memory, or other non-volatile solid-state memory. In some examples, the memory may further include a memory remotely arranged relative to the processor, and these remote memories may be connected to the mobile terminal via a network. Examples of the above-mentioned network include, but are not limited to, the Internet, an intranet, a local area network, a mobile communication network, and combinations thereof.

[0047] Optionally, the communication transmission device can be used to receive or send data via a network, which may include a wireless network provided by a communication provider of the mobile terminal. The communication transmission device may include a NIC (Network Interface Controller) that can be connected to other network devices through a base station so as to communicate with the Internet.

[0048] The technical solutions in the embodiments of the present application will be described in detail below in conjunction with the drawings in the embodiments of the present application.

[0049] See also Figure 4 , which is a flow chart of the microcurrent control method described in this application in one embodiment. Figure 4 As shown, an embodiment of the present application provides a microcurrent control method, which includes the following steps S100 to S400.

[0050] In step S100, the current change at the output end of the micro-current controller is monitored in real time.

[0051] See also Figure 5 , which is a flow chart of another embodiment of the microcurrent control method described in this application. Figure 5 As shown, real-time monitoring of current changes at the output end of the micro-current controller may include the following steps S101 to S105, wherein steps S101 and S102 may be executed by a first current sampling circuit, and steps S103 to S105 may be executed by an MCU microcontroller.

[0052] In step S101, the original current signal output by the microcurrent controller is collected as the first current signal.

[0053] In the embodiment of the present application, the original current signal output by the microcurrent controller, namely the first current signal I0, is collected by the first current sampling circuit. The first current signal I0 is a current signal that does not flow through the treatment area of ​​the patient.

[0054] In step S102, the first current signal is digitized to obtain a corresponding first current value.

[0055] In one embodiment of the present application, the first current sampling circuit includes an ADC analog-to-digital converter, an Op-Amp operational amplifier, and a shunt resistor, which are used to collect, amplify and convert the first current signal, thereby realizing digital processing of the first current signal.

[0056] Specifically, the Op-Amp operational amplifier is used to amplify the voltage signal to improve the accuracy and anti-interference ability of the signal. The amplified voltage signal is converted into a digital signal through the high-precision shunt resistor and the ADC analog-to-digital converter, and the current value, i.e., the first current value, is calculated at the same time.

[0057] In step S103, the first current values ​​are stored in a first array of preset capacity in the order of acquisition time.

[0058] In an embodiment of the present application, the first array is represented as D0, and the first array D0 is used to store N data samples.

[0059] It should be noted that the N value in the embodiment of the present application can be adjusted through the firmware program according to actual needs to meet the needs of different application scenarios.

[0060] In step S104, the standard deviation values ​​of all samples in the first array are calculated in real time.

[0061] Specifically, after the first array D0 stores N samples, the MCU calculates the standard deviation of the N samples. The standard deviation is an important statistical indicator for measuring the degree of data dispersion and can reflect the fluctuation of the current signal.

[0062] In step S105, the first array is dynamically updated based on the first-in-first-out principle.

[0063] Specifically, the MCU will check whether the first array D0 has reached its storage limit. If the storage limit has not been reached, the newly acquired first current value will be directly added to the end of the first array. If the first array D0 has reached the storage limit, the newly acquired first current value will replace the earliest stored first current value in the first array D0. This means that the first element of the first array D0 (i.e., the earliest stored value) will be removed, and the newly acquired first current value will be added to the end of the array D0. Since the content of the first array D0 has been updated, the calculation of the standard deviation value will be based on the updated first array.

[0064] In this implementation, the current output by the microcurrent controller can be stably and effectively monitored, and has the advantage of low error. In traditional current monitoring methods, only a single value of the current is often calculated and judged. When a strict threshold is used, fluctuations in individual values ​​will frequently trigger system warnings. In this application, a dynamic standard deviation value calculation method is used to calculate a batch of continuously updated dynamic data. The obtained value can reflect the overall change of the current, reduce the impact of individual value jumps, and at the same time maintain strict monitoring standards and optimize the judgment logic of microcurrent fluctuations.

[0065] In step S200, the skin impedance change of the patient when the microcurrent flows through the treatment area is monitored in real time.

[0066] In the embodiments of the present application, the skin impedance refers to the degree of resistance of the skin to the current, which may change due to a variety of factors, such as skin humidity, temperature, contact area, etc. Different skin conditions correspond to different skin impedances. If the skin resistance changes too much, for example, due to poor contact caused by sweat or dry skin, the quality of current transmission may be reduced.

[0067] The treatment area covers the entire skin of the patient, including the forehead and the bottom of the eyes, etc. The actual action area of ​​riboflavin is the cornea.

[0068] See also Figure 6 , which is a flow chart of the microcurrent control method described in this application in another embodiment. Figure 6 As shown, real-time monitoring of the patient's skin impedance changes when the microcurrent flows through the treatment area includes the following steps S201 to S211, wherein steps S201 and S202 can be executed by the second current sampling circuit, steps S206 and S207 can be executed by the voltage drop sampling circuit, and steps S203 to S204 and steps S208 to S211 can be executed by the MCU microcontroller.

[0069] In step S201, a current signal flowing through the treatment area is collected as a second current signal.

[0070] In the embodiment of the present application, a current signal flowing through the treatment area, ie, the second current signal IReal, is collected by a second current sampling circuit.

[0071] In step S202, the second current signal is digitized to obtain a corresponding second current value.

[0072] In one embodiment of the present application, the second current sampling circuit includes an ADC analog-to-digital converter, an Op-Amp operational amplifier, and a shunt resistor, which are used to collect, amplify and convert the second current signal, thereby realizing digital processing of the second current signal.

[0073] Specifically, the Op-Amp operational amplifier is used to amplify the voltage signal to improve the accuracy and anti-interference ability of the signal. The amplified voltage signal is converted into a digital signal through the high-precision shunt resistor and the ADC analog-to-digital converter, and the current value, i.e., the second current value, is calculated at the same time.

[0074] In step S203, the second current values ​​are stored in a second array of preset capacity in the order of acquisition time.

[0075] In an embodiment of the present application, the second array is represented as DReal, and the second array DReal is used to store N data samples.

[0076] It should be noted that the N value in the embodiment of the present application can be adjusted through the firmware program according to actual needs to meet the needs of different application scenarios.

[0077] In step S204, the average value of all samples in the second array is calculated to obtain the current average value.

[0078] Specifically, after the second array DReal stores N samples, the MCU calculates the current average value of the N samples. The current average value reflects the stability of the current over a period of time. By calculating the current average value, the real current value can be better reflected, especially in the presence of fluctuations or interference, the reading of a single sample may be inaccurate, and the average value can provide a more accurate estimate.

[0079] In step S205, the second array is dynamically updated based on the first-in-first-out principle.

[0080] Specifically, the MCU will check whether the second array DReal has reached its storage upper limit. If the storage upper limit has not been reached, the newly acquired second current value will be directly added to the end of the array. If the second array DReal has reached its storage upper limit, the newly acquired second current value will replace the earliest stored second current value in the second array DReal. This means that the first element of the second array DReal (i.e., the earliest stored second current value) will be removed, and the newly acquired second current value will be added to the end of the second array DReal. Since the content of the second array DReal has been updated, the calculation of the current average value will be based on the updated second array.

[0081] In step S206, the voltage drop signal across the output end of the micro-current controller is collected.

[0082] In the embodiment of the present application, the voltage drop signal at both ends of the output end of the micro-current controller is collected by a voltage drop sampling circuit and is represented as UReal.

[0083] In step S207, the voltage drop signal is digitally processed to obtain a corresponding voltage drop value.

[0084] In one embodiment of the present application, the voltage drop sampling circuit includes a voltage sensor, a differential amplifier, and an ADC analog-to-digital converter.

[0085] Specifically, the voltage sensor is used to directly measure the voltage signals at the two output ends of the microcurrent controller, and calculate the potential difference between the two as a voltage drop signal; the differential amplifier is used to amplify the weak voltage drop signal, while suppressing common mode noise and improving measurement accuracy; the ADC analog-to-digital converter is used to convert the amplified analog voltage signal into a digital signal, and the conversion result is a digital value, namely the voltage drop value.

[0086] In step S208, the voltage drop values ​​are stored in a third array of preset capacity in the order of acquisition time.

[0087] In an embodiment of the present application, the third array is represented as UReal, and the third array Real is used to store N data samples.

[0088] It should be noted that the N value in the embodiment of the present application can be adjusted through the firmware program according to actual needs to meet the needs of different application scenarios.

[0089] In step S209, the average value of all samples in the third array is calculated to obtain the voltage drop average value.

[0090] Specifically, after the third array UReal stores N samples, the MCU calculates the average voltage drop of the N samples. The average voltage drop reflects the stability of the voltage between the two output terminals of the microcurrent controller over a period of time. By calculating the average voltage drop, the real voltage value can be better reflected, especially in the presence of fluctuations or interference, the reading of a single sample may be inaccurate, and the average value can provide a more accurate estimate.

[0091] In step S210, the third array is dynamically updated based on a first-in-first-out principle.

[0092] Specifically, the MCU will check whether the third array UReal has reached its storage upper limit. If the storage upper limit has not been reached, the newly acquired average voltage drop value will be directly added to the end of the third array UReal. If the third array UReal has reached its storage upper limit, the newly acquired average voltage drop value will replace the earliest stored average voltage drop value in the third array UReal. This means that the first element of the third array UReal (i.e., the earliest stored average voltage drop value) will be removed, and the newly acquired average voltage drop value will be added to the end of the third array UReal. Since the content of the third array UReal has been updated, the calculation of the average voltage drop value will be based on the updated third array.

[0093] In step S211, a skin impedance value is calculated based on the current average value and the voltage drop average value.

[0094] In one embodiment of the present application, the ratio of the voltage drop average value to the current average value represents the skin impedance value.

[0095] Within the preset time period, at regular intervals, such as 0.1 seconds or 1 second, the data points of skin impedance values ​​are continuously collected to form a time series Z 1 , Z 2 , Z 3 , …, Z n .

[0096] These time series data are analyzed to observe the changing trend of skin impedance values ​​over time. Simple mathematical methods (such as calculating the difference or slope of adjacent data points) can be used to determine whether there is an obvious upward trend, downward trend or fluctuation. For example, calculate the difference ΔZ of adjacent data points i =Z i+1 -Z i , if multiple ΔZ i If it is greater than a certain fixed value, it indicates that the skin impedance is on an upward trend, that is, the skin impedance is increasing.

[0097] In step S300, based on the current change and / or the skin impedance change, a standard evaluation is performed on the magnitude of the microcurrent acting on the treatment area.

[0098] See also Figure 7 , which is a flow chart of the microcurrent control method described in this application in another embodiment. Figure 7 As shown, based on the current change, a standard evaluation is performed on the size of the microcurrent acting on the treatment area, including: determining whether the current value stored in the first array is always zero; if so, issuing an electrode disconnection warning; otherwise, comparing the standard variance value with a preset tolerance range; if the standard variance value is greater than the preset tolerance range, determining that the size of the microcurrent acting on the treatment area does not meet the standard, and issuing a current fluctuation warning; otherwise, determining that the size of the microcurrent acting on the treatment area meets the standard.

[0099] The embodiment of the present application also includes: when it is determined that the size of the microcurrent acting on the treatment area does not meet the standard, the MCU microcontroller will light up the current fluctuation indicator light on the display device based on the current fluctuation warning. When it is determined that the size of the microcurrent acting on the treatment area meets the standard, the MCU microcontroller will keep the current fluctuation indicator light on the display device off.

[0100] In one embodiment of the present application, based on the change in skin impedance, a standard evaluation is performed on the size of the microcurrent acting on the treatment area, including: comparing the skin impedance value with a preset normal range; if the skin impedance value is within the preset normal range, it is determined that the size of the microcurrent acting on the treatment area meets the standard; otherwise, it is determined that the size of the microcurrent acting on the treatment area does not meet the standard, and a poor contact warning is issued.

[0101] For example, the normal range can be set to (nKΩ, NKΩ), where n and N can be preset by the firmware program. If the skin impedance value is within the (nKΩ, NKΩ) interval, the size of the microcurrent will be determined to be up to standard. This means that the resistance of the current through the skin is within an acceptable range and will not cause discomfort or harm to the patient. If the skin impedance value exceeds the (nKΩ, NKΩ) interval, the size of the microcurrent will be determined to be not up to standard. This may indicate a poor contact problem, such as the electrode sheet not fitting the skin properly, or sweat, oil, etc. on the skin surface affecting the conduction of current.

[0102] In step S400, the microcurrent that does not meet the standard is dynamically adjusted to achieve a standard output of the microcurrent.

[0103] In one embodiment of the present application, the microcurrent that does not meet the standards is dynamically adjusted to achieve the standard output of the microcurrent, including: if the skin impedance value is higher than the preset normal range, reducing the resistance value of the digital potentiometer to increase the value of the microcurrent; if the skin impedance value is lower than the preset normal range, increasing the resistance value of the digital potentiometer to reduce the value of the microcurrent.

[0104] In the embodiment of the present application, the resistance value of the digital potentiometer is inversely proportional to the value of the microcurrent. This means that when the resistance value of the digital potentiometer increases, the value of the microcurrent will decrease accordingly; conversely, when the resistance value of the digital potentiometer decreases, the value of the microcurrent will increase. By dynamically adjusting the resistance value of the digital potentiometer, the size of the output microcurrent can be accurately controlled to adapt to different skin impedance conditions and ensure the stability and safety of the microcurrent.

[0105] In another embodiment of the present application, dynamically adjusting the microcurrent that does not meet the standards to achieve standard output of the microcurrent includes: comparing the current average value with a preset target treatment current parameter, and determining whether the current average value is within the target current tolerance range; if the current average value> the target treatment current parameter, and the current average value is outside the target current tolerance range, increasing the resistance value of the digital potentiometer to reduce the value of the microcurrent; if the current average value< the target treatment current parameter, and the current average value is outside the target current tolerance range, reducing the resistance value of the digital potentiometer to increase the value of the microcurrent; if the current average value is within the target current tolerance range, maintaining the resistance value of the digital potentiometer unchanged.

[0106] In this implementation, by dynamically adjusting the microcurrent that does not meet the standards, the deviated current can be dynamically self-corrected during the treatment process, ensuring a stable, safe and effective treatment effect.

[0107] It should be noted that the protection scope of the microcurrent control method described in the embodiment of the present application is not limited to the execution order of the steps listed in this embodiment. All solutions implemented by adding, reducing or replacing steps in the prior art based on the principles of the present application are included in the protection scope of the present application.

[0108] See also Figure 8 , which is a schematic diagram of the structure of an electronic device described in this application in one embodiment. Figure 8 As shown, an embodiment of the present application provides an electronic device, including: a processor and a memory.

[0109] The memory is used to store computer programs.

[0110] The processor is used to execute the computer program stored in the memory so that the drone network deployment and collaborative cache terminal execute any of the microcurrent control methods described above.

[0111] Preferably, the processor may be a general-purpose processor, including a central processing unit (CPU), a network processor (NP), etc.; it may also be a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), or other programmable logic devices, discrete gates or transistor logic devices, discrete hardware components. The memory may be implemented by any type of volatile or non-volatile storage device or a combination thereof, such as a static random access memory (SRAM), an electrically erasable programmable read-only memory (EEPROM), an erasable programmable read-only memory (EPROM), a programmable read-only memory (PROM), a read-only memory (ROM), a magnetic memory, a flash memory, a magnetic disk or an optical disk.

[0112] In the several embodiments provided in the present application, it should be understood that the disclosed system, device or method can be implemented in other ways. For example, the device embodiments described above are only schematic. For example, the division of modules / units is only a logical function division. There may be other division methods in actual implementation, such as multiple modules or units can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be an indirect coupling or communication connection through some interfaces, devices or modules or units, which can be electrical, mechanical or other forms.

[0113] The modules / units described as separate components may or may not be physically separated, and the components displayed as modules / units may or may not be physical modules, that is, they may be located in one place, or they may be distributed on multiple network units. Some or all of the modules / units may be selected according to actual needs to achieve the purpose of the embodiments of the present application. For example, the functional modules / units in the various embodiments of the present application may be integrated into one processing module, or each module / unit may exist physically separately, or two or more modules / units may be integrated into one module / unit.

[0114] Those of ordinary skill in the art should further appreciate that the units and algorithm steps of each example described in conjunction with the embodiments disclosed herein can be implemented in electronic hardware, computer software, or a combination of the two. In order to clearly illustrate the interchangeability of hardware and software, the composition and steps of each example have been generally described in the above description according to function. Whether these functions are performed in hardware or software depends on the specific application and design constraints of the technical solution. Professional and technical personnel can use different methods to implement the described functions for each specific application, but such implementation should not be considered to be beyond the scope of this application.

[0115] An embodiment of the present application also provides a computer-readable storage medium on which a computer program is stored. When the computer program is executed by a processor, the above-mentioned microcurrent control method is implemented.

[0116] A person of ordinary skill in the art can understand that all or part of the steps in the method for implementing the above-mentioned embodiment can be completed by instructing a processor through a program, and the program can be stored in a computer-readable storage medium, and the storage medium is a non-transitory medium, such as a random access memory, a read-only memory, a flash memory, a hard disk, a solid-state hard disk, a magnetic tape, a floppy disk, an optical disc, and any combination thereof. The above-mentioned storage medium can be any available medium that can be accessed by a computer or a data storage device such as a server or a data center that includes one or more available media. The available medium can be a magnetic medium (for example, a floppy disk, a hard disk, a tape), an optical medium (for example, a digital video disc (DVD)), or a semiconductor medium (for example, a solid-state disk (SSD)), etc.

[0117] The present application embodiment may also provide a computer program product, the computer program product including one or more computer instructions. When the computer instructions are loaded and executed on a computing device, the process or function described in the embodiment of the present application is generated in whole or in part. The computer instructions may be stored in a computer-readable storage medium, or transmitted from one computer-readable storage medium to another computer-readable storage medium, for example, the computer instructions may be transmitted from a website site, computer or data center by wired (e.g., coaxial cable, optical fiber, digital subscriber line (DSL)) or wireless (e.g., infrared, wireless, microwave, etc.) mode to another website site, computer or data center.

[0118] When the computer program product is executed by a computer, the computer executes the method described in the above method embodiment. The computer program product may be a software installation package, and when the above method is required, the computer program product may be downloaded and executed on a computer.

[0119] The descriptions of the processes or structures corresponding to the above-mentioned figures have different emphases. For parts that are not described in detail in a certain process or structure, please refer to the relevant descriptions of other processes or structures.

[0120] The above embodiments are merely illustrative of the principles and effects of the present application and are not intended to limit the present application. Anyone familiar with the technology may modify or change the above embodiments without violating the spirit and scope of the present application. Therefore, all equivalent modifications or changes made by a person of ordinary skill in the art without departing from the spirit and technical ideas disclosed in the present application shall still be covered by the claims of the present application.

Claims

1. A microcurrent control method, applied to a riboflavin ion introduction device in corneal cross-linking, characterized in that: The riboflavin ion introduction device comprises a microcurrent controller; the microcurrent controller is electrically connected to a DC power supply and is used to convert a constant current provided by the DC power supply into a microcurrent; the microcurrent control method comprises: Real-time monitoring of current changes at the output end of the micro-current controller; Real-time monitoring of the patient's skin impedance changes when the microcurrent flows through the treatment area; Based on the current change and / or the skin impedance change, a standard evaluation is performed on the magnitude of the microcurrent acting on the treatment area; The microcurrent that does not meet the standards is dynamically adjusted to achieve the standard output of the microcurrent.

2. The method according to claim 1, characterized in that Real-time monitoring of the current change at the output end of the micro-current controller includes: Collecting the original current signal output by the microcurrent controller as the first current signal; Digitally processing the first current signal to obtain a corresponding first current value; The first current values ​​are stored in a first array of preset capacity in the order of acquisition time; Calculating standard deviation values ​​of all samples in the first array in real time; Based on the first-in-first-out principle, the first array is dynamically updated.

3. The method according to claim 2, characterized in that Based on the current changes, a standard assessment of the magnitude of the microcurrent acting on the treatment area includes: Determining whether the current value stored in the first array is always zero; If so, an electrode disconnection warning is issued; Otherwise, the standard deviation value is compared with a preset tolerance range; If the standard deviation value is greater than the preset tolerance range, it is determined that the magnitude of the microcurrent acting on the treatment area does not meet the standard, and a current fluctuation warning is issued; Otherwise, it is determined that the magnitude of the microcurrent acting on the treatment area meets the standard.

4. The method according to claim 1, characterized in that: Real-time monitoring of the patient's skin impedance changes when the microcurrent flows through the treatment area includes: collecting a current signal flowing through the treatment area as a second current signal; Digitally processing the second current signal to obtain a corresponding second current value; storing the second current values ​​in a second array of preset capacity in the order of acquisition time; Calculating the average value of all samples in the second array to obtain the current average value; Dynamically updating the second array based on a first-in-first-out principle; Collecting voltage drop signals at both ends of the output end of the micro-current controller; Digitally processing the voltage drop signal to obtain a corresponding voltage drop value; The voltage drop values ​​are stored in a third array of preset capacity in the order of acquisition time; Calculating the average value of all samples in the third array to obtain a voltage drop average value; Dynamically updating the third array based on a first-in-first-out principle; A skin impedance value is calculated based on the current average value and the voltage drop average value.

5. The method according to claim 4, characterized in that Based on the skin impedance change, a standard assessment of the magnitude of the microcurrent acting on the treatment area includes: Comparing the skin impedance value with a preset normal range; If the skin impedance value is within a preset normal range, it is determined that the magnitude of the microcurrent acting on the treatment area meets the standard; Otherwise, it is determined that the magnitude of the microcurrent acting on the treatment area does not meet the standard, and a poor contact warning is issued.

6. The method according to claim 4, characterized in that Dynamically adjusting the microcurrent that does not meet the standard to achieve the standard output of the microcurrent includes: If the skin impedance value is higher than the preset normal range, the resistance value of the digital potentiometer is reduced to increase the value of the microcurrent; the resistance value of the digital potentiometer is inversely proportional to the value of the microcurrent; If the skin impedance value is lower than the preset normal range, the resistance value of the digital potentiometer is increased to reduce the value of the microcurrent.

7. The method according to claim 4, characterized in that Dynamically adjusting the microcurrent that does not meet the standards to achieve stable output of the microcurrent includes: Comparing the current average value with a preset target treatment current parameter, and determining whether the current average value is within a target current tolerance range; If the current average value is greater than the target treatment current parameter, and the current average value is outside the target current tolerance range, then the resistance value of the digital potentiometer is increased to reduce the value of the microcurrent; If the current average value is less than the target treatment current parameter, and the current average value is outside the target current tolerance range, then reducing the resistance value of the digital potentiometer to increase the value of the microcurrent; If the current average value is within the target current tolerance range, the resistance value of the digital potentiometer is maintained unchanged.

8. A corneal ion introduction system, characterized in that: include: A direct current power supply, wherein the direct current power supply is used to provide a constant current; A riboflavin ion introduction device, comprising a microcurrent controller; the microcurrent controller is electrically connected to the DC power supply and is used to execute the microcurrent control method as described in any one of claims 1 to 7.

9. The system according to claim 8, characterized in that The riboflavin ion introduction device also includes a corneal drug delivery device; the corneal drug delivery device includes a reservoir for storing riboflavin solution, a negative electrode network and an electrical connector; the bottom of the reservoir is provided with a fitting surface for fitting the cornea, and the upper end of the reservoir is formed with a drug delivery port; the negative electrode network is embedded in the reservoir and contacts with the riboflavin solution in the reservoir; the electrical connector is provided on the outer wall of the reservoir and is connected to the negative electrode network.

10. The system according to claim 9, characterized in that The microcurrent controller includes an input end and two output ends, wherein the input end is connected to the DC power supply, one output end is electrically connected to the negative electrode network through the electrical connector, and the other output end is electrically connected to the patient's skin.

11. An electronic device, characterized in that: include: Memory for storing computer programs and firmware programs; A processor is used to execute the computer program stored in the memory so that the electronic device executes the microcurrent control method according to any one of claims 1 to 7.

12. A computer-readable storage medium having a computer program stored thereon, characterized in that: When the computer program and the firmware program are executed by a processor, the microcurrent control method according to any one of claims 1 to 7 is implemented.

Images